skip navigationU S P T O SealUnited States Patent and Trademark Office TTABVUE logo
Home|Site Index|Search|Guides|Contacts|eBusiness|eBiz alerts|News|Help
TTABVUE. Trademark Trial and Appeal Board Inquiry System
v2.5.0

Opposition

Number:91287565Filing Date:10/10/2023
Status:TerminatedStatus Date:06/04/2024
General Contact Number:571-272-8500
Interlocutory Attorney:MARY B MYLES
Paralegal Name:AMY L MATELSKI
Defendant Serial/Reg. No. also in terminated case(s):91287537
Defendant
Name:AltruBio Inc.
Correspondence:JOHN C. CAIN
MUNCK WILSON MANDALA, LLP
1330 POST OAK BLVD., STE 2850
HOUSTON, TX 77056
UNITED STATES
fmtrademarks@munckwilson.com, jcain@munckwilson.com, crifai@munckwilson.com
Phone: 832-615-2744
 
Serial #:97329609Application FileAssignmentRegistration #:7436019
Application Status: REGISTERED
Mark: ALTRUBIO
Plaintiff
Name:Bausch Health Ireland Limited
Correspondence:WILLIAM S. FULTZ
WOMBLE BOND DICKINSON (US) LLP
555 FAYETTEVILLE STREET, SUITE 1100
RALEIGH, NC 27601
UNITED STATES
tmdocketing@wbd-us.com, evan.fultz@wbd-us.com, kelli.ovies@wbd-us.com, alice.rogers@wbd-us.com, TMDocketing@bauschhealth.com
Phone: 919-755-2100
 
Serial #:87022985Application FileAssignmentRegistration #:5807207
Application Status: REGISTERED
Mark: ALTRENO
 
Serial #:88506343Application FileAssignmentRegistration #:6067127
Application Status: REGISTERED
Mark: ALTRENO (TRETINOIN) LOTION, 0.05%
Prosecution History
#DateHistory TextDue Date
1406/04/2024TERMINATED
1306/04/2024BD DECISION: OPP DISMISSED
1205/23/2024D RESP TO BD ORDER/INQUIRY
1104/30/2024RESPONSE DUE 30 DAYS (DUE DATE)05/30/2024
1003/21/2024MOT TO AMEND APPLICATION
902/20/2024AMDT DENIED; RESP DUE
802/13/2024MOT TO AMEND APPLICATION
701/18/2024EXTENSION OF TIME GRANTED
601/18/2024D MOT FOR EXT W/ CONSENT
511/16/2023SUSPENDED
411/16/2023D MOT TO SUSP W/ CONSENT PEND SETTL NEGOTIATIONS
310/10/2023INSTITUTED
210/10/2023NOTICE AND TRIAL DATES SENT; ANSWER DUE:11/19/2023
110/10/2023FILED AND FEE
Results as of 11/22/2024 12:49 AM
| .HOME | INDEX| SEARCH | eBUSINESS | CONTACT US | PRIVACY POLICY